CDC ‘Dear Colleague’ Letter: FDA’s Drug Safety Communication on DTG

The Centers for Disease Control and Prevention released a ‘Dear Colleague’ letter regarding the U.S. Food and Drug Administration’s Drug Safety Communication on the potential risk of antiretroviral medication dolutegravir (DTG) associated neural tube birth defects.

Read the letter.

About Kim Rodgers

Kim Rodgers serves as a Communications Specialist at NACCHO. Her work includes promoting local health departments' best practices, as well as partner tools and resources, in infectious disease and preparedness through NACCHO's communications channels, storytelling, and outreach to various audiences.

Leave a Reply

Your email address will not be published. Required fields are marked *